NASDAQ:GLPG Galapagos - GLPG Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. $43.40 -0.27 (-0.62%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$43.05▼$44.0750-Day Range$37.44▼$48.0052-Week Range$37.24▼$72.11Volume111,414 shsAverage Volume105,719 shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice Target$52.46 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Galapagos MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside20.9% Upside$52.46 Price TargetShort InterestHealthy1.53% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.84) to ($3.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector841st out of 1,030 stocksPharmaceutical Preparations Industry417th out of 502 stocks 3.0 Analyst's Opinion Consensus RatingGalapagos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.46, Galapagos has a forecasted upside of 20.9% from its current price of $43.40.Amount of Analyst CoverageGalapagos has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.53% of the outstanding shares of Galapagos have been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Galapagos has recently decreased by 12.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalapagos does not currently pay a dividend.Dividend GrowthGalapagos does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLPG. Previous Next 1.3 News and Social Media Coverage News SentimentGalapagos has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for GLPG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Galapagos to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galapagos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Galapagos is held by insiders.Percentage Held by InstitutionsOnly 19.45% of the stock of Galapagos is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Galapagos are expected to decrease in the coming year, from ($1.84) to ($3.25) per share.Price to Book Value per Share RatioGalapagos has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Galapagos (NASDAQ:GLPG) StockGalapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.Read More Receive GLPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. Email Address GLPG Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comGalapagos (NASDAQ:GLPG) Shares Gap Up to $45.82January 23, 2023 | americanbankingnews.comGalapagos (NASDAQ:GLPG) Rating Increased to Hold at Jefferies Financial GroupFebruary 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.January 3, 2023 | finance.yahoo.comGalapagos to present at 41th Annual J.P. Morgan Healthcare ConferenceDecember 28, 2022 | finance.yahoo.com3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023December 22, 2022 | finance.yahoo.comGalapagos announces changes to Executive CommitteeDecember 20, 2022 | finance.yahoo.comOn A Mission As Top European Player, Galapagos Looks For Acquisition TargetsDecember 16, 2022 | finance.yahoo.comDoes Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?February 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.December 13, 2022 | finance.yahoo.comGalapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-careDecember 8, 2022 | finance.yahoo.comDown 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a TurnaroundNovember 10, 2022 | tmcnet.comGalapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022November 2, 2022 | finance.yahoo.comStrong week for Galapagos (AMS:GLPG) shareholders doesn't alleviate pain of three-year lossOctober 26, 2022 | finance.yahoo.comGalapagos NV (GLPG.AS)October 19, 2022 | wsj.comGalapagos N.V. ADROctober 17, 2022 | globenewswire.comGalapagos to host its R&D Update 2022 in New York on 4 November 2022 - GlobeNewswireOctober 17, 2022 | finance.yahoo.comGalapagos to host its R&D Update 2022 in New York on 4 November 2022October 16, 2022 | reuters.comQuake strikes in Pacific off Central America, no reports of damage - ReutersOctober 15, 2022 | reuters.comGLPG.AS - Galapagos NV | Stock Price & Latest News | ReutersOctober 15, 2022 | markets.businessinsider.comExpert Ratings for GalapagosOctober 13, 2022 | benzinga.comExpert Ratings for Galapagos - Galapagos (NASDAQ:GLPG) - BenzingaOctober 10, 2022 | seekingalpha.comGalapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product (NASDAQ:GLPG) - Seeking AlphaOctober 9, 2022 | forbes.comScenic And Uncrowded Fall, Nepal To The Galapagos: Trek, Glamp, Bike, RV - ForbesOctober 8, 2022 | nasdaq.comGalapagos NV - ADR Shares Close in on 52-Week Low - Market Mover - NasdaqOctober 6, 2022 | globenewswire.comGalapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress - GlobeNewswireOctober 6, 2022 | finance.yahoo.comGalapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congressOctober 6, 2022 | usatoday.comA fly threatens Galapagos archipelago - USA TODAYSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. Email Address GLPG Company Calendar Today2/02/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLPG CUSIPN/A CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,309Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.46 High Stock Price Forecast$70.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+20.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-122,130,000.00 Net Margins1.13% Pretax Margin2.34% Return on Equity0.25% Return on Assets0.13% Debt Debt-to-Equity RatioN/A Current Ratio8.38 Quick Ratio8.34 Sales & Book Value Annual Sales$573.66 million Price / Sales4.98 Cash FlowN/A Price / Cash FlowN/A Book Value$47.71 per share Price / Book0.91Miscellaneous Outstanding Shares65,840,000Free Float63,920,000Market Cap$2.86 billion OptionableOptionable Beta0.31 Key ExecutivesPaulus StoffelsChairman & Chief Executive OfficerBart FiliusPresident, Chief Operating & Financial OfficerMichele MantoChief Commercial OfficerPhil DudfieldManaging Director-FideltaSandra CauwenberghsDirector-Investor RelationsKey CompetitorsIVERIC bioNASDAQ:ISEEHarmony BiosciencesNASDAQ:HRMYBausch Health CompaniesNYSE:BHCRevance TherapeuticsNASDAQ:RVNCInsmedNASDAQ:INSMView All CompetitorsInsiders & InstitutionsMonaco Asset Management SAMBought 8,678 shares on 1/31/2023Ownership: 0.028%XR Securities LLCBought 6,600 shares on 1/23/2023Ownership: 0.000%Jane Street Group LLCSold 78,910 shares on 11/16/2022Ownership: 0.101%Balyasny Asset Management LLCBought 8,147 shares on 11/16/2022Ownership: 0.012%Endurant Capital Management LPSold 588 shares on 11/15/2022Ownership: 0.077%View All Institutional Transactions GLPG Stock - Frequently Asked Questions Should I buy or sell Galapagos stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last twelve months. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares. View GLPG analyst ratings or view top-rated stocks. What is Galapagos' stock price forecast for 2023? 7 Wall Street research analysts have issued 12 month price targets for Galapagos' stock. Their GLPG share price forecasts range from $40.00 to $70.00. On average, they expect the company's stock price to reach $52.46 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price. View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts. How have GLPG shares performed in 2023? Galapagos' stock was trading at $44.38 at the beginning of the year. Since then, GLPG shares have decreased by 2.4% and is now trading at $43.33. View the best growth stocks for 2023 here. Are investors shorting Galapagos? Galapagos saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 1,010,000 shares, a decrease of 12.9% from the December 31st total of 1,160,000 shares. Based on an average daily volume of 174,300 shares, the short-interest ratio is currently 5.8 days. View Galapagos' Short Interest. When is Galapagos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our GLPG earnings forecast. What is Onno van de Stolpe's approval rating as Galapagos' CEO? 6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Galapagos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL). When did Galapagos IPO? (GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. What is Galapagos' stock symbol? Galapagos trades on the NASDAQ under the ticker symbol "GLPG." Who are Galapagos' major shareholders? Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Monaco Asset Management SAM (0.03%), XR Securities LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Galapagos? Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galapagos' stock price today? One share of GLPG stock can currently be purchased for approximately $43.33. How much money does Galapagos make? Galapagos (NASDAQ:GLPG) has a market capitalization of $2.85 billion and generates $573.66 million in revenue each year. How many employees does Galapagos have? The company employs 1,309 workers across the globe. How can I contact Galapagos? Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The official website for the company is www.glpg.com. The biotechnology company can be reached via phone at (321) 534-2900, via email at ir@glpg.com, or via fax at 321-534-2901. This page (NASDAQ:GLPG) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.